This guideline includes statements and recommendations based on available, high-level evidence about the use of taxanes in adjuvant and neoadjuvant chemotherapy regimens for the treatment of women with early (operable) breast cancer. The guideline aims to provide health professionals with information to assist in making management recommendations for improved patient outcomes. National Breast and Ovarian Cancer Centre (NBOCC)* also develops information specifically for consumers about early breast cancer diagnosis and treatment options.
For information on the Pharmaceutical Benefits Scheme (PBS) listing for taxanes, please see PBS section of this guideline.
A clinical practice guideline developed by National Breast And Ovarian Cancer Centre (NBOCC)*
This document supplements systemic adjuvant therapy guideline recommendations 12–22 (pp 8–10), specifically those about chemotherapy regimens contained in the National Breast Cancer Centre* Clinical practice guidelines for the management of early breast cancer, 2nd edition 2001.
Incorporates published evidence to March 2007
- The Faculty of Radiation Oncology - The Royal Australian and New Zealand College of Radiologists
- The Royal Australasian College of Physicians
- The Royal Australasian College of Surgeons
ISBN Print: 978-1-74127-116-4
ISBN Online: 978-1-74127-117-1
© Cancer Australia 2011
* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.
|Guideline Topic||Early breast cancer|
|Cancer Types||Breast cancer|
This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.